# A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Paricalcitol For Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Participants With Stage 5 Chronic Kidney Disease (CKD)

> **NCT04064827** · PHASE3 · TERMINATED · sponsor: **AbbVie** · enrollment: 2 (actual)

## Conditions studied

- Chronic Kidney Disease (CKD)
- Secondary Hyperparathyroidism (SHPT)

## Interventions

- **DRUG:** Paricalcitol

## Key facts

- **NCT ID:** NCT04064827
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-09-16
- **Primary completion:** 2025-06-09
- **Final completion:** 2025-06-09
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Company Decision
- **Last updated:** 2025-12-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04064827

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04064827, "A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Paricalcitol For Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Participants With Stage 5 Chronic Kidney Disease (CKD)". Retrieved via AI Analytics 2026-05-21 from https://api.ai-analytics.org/clinical/NCT04064827. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*